Seneca Biopharma and Jiangsu QYuns Therapeutics Announce Development Plan for Potential Joint Pipeline at 7th China Renaissance Healthcare and Life Science Leadership Summit Nov 1, 2019
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases Oct 30, 2019
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients Sep 24, 2019